Related Experiment Video
Updated: Jun 22, 2026
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Increased platelet activation in patients with slow coronary flow
Turgay Celik1, U Cagdas Yuksel, Baris Bugan
1The Department of Cardiology, Gulhane Military Medical Academy, GATA Kardiyoloji A.D, 06018, Etlik, Ankara, Turkey. benturgay@yahoo.com
Journal of Thrombosis and Thrombolysis
|June 5, 2009
Summary
Platelet activation is elevated in patients with slow coronary flow (SCF), indicated by higher mean platelet volume (MPV) and sP-selectin levels. This suggests increased platelet activity contributes to the development of slow coronary flow phenomenon (SCFP).
Area of Science:
- Cardiology
- Hematology
- Pathophysiology
Background:
- Slow coronary flow phenomenon (SCFP) is a condition affecting coronary artery blood flow.
- The role of platelet activation in SCF pathogenesis remains unclear.
Purpose of the Study:
- To investigate whether increased platelet activation is present in patients with SCF.
- To determine if platelet activation contributes to the development of SCF.
Main Methods:
- Compared 50 SCF patients with 50 controls using Thrombolysis In Myocardial Infarction (TIMI) frame count.
- Measured mean platelet volume (MPV) and plasma sP-selectin levels in both groups.
Main Results:
- SCF patients had significantly higher MPV and sP-selectin levels than controls.
- MPV and sP-selectin levels positively correlated with TIMI frame counts in SCF patients.
Conclusions:
- Platelet activity is demonstrably increased in patients with SCF.
- Elevated platelet activation may play a role in the pathogenesis of SCF.
Related Concept Videos
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
01:30Peripheral Artery Disease I: Introduction
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...